ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Yin, Shuangneng; Chen, Zhaojun; Chen, Dugang*; Yan, Dan*武汉工程大学
2023DOI: 10.7150/thno.80091
16被引6阅读
引用收藏
分享

摘要

Immunotherapy has achieved great success recently and opened a new avenue for anti-tumor treatment. Programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) are typical immune checkpoints that transmit coinhibitory signals, muting the host immunity. Monoclonal antibodies that block PD-1/PD-L1 axis have benefited many patients with different tumor diseases. However, the objective response rate is still unsatisfactory. In this review, we summarize three strategies targeting PD-L1 based on different forms of PD-L1 and various regulating mechanisms to enhance the therapeutic effect, including blockade of the interaction between PD-L1 and PD-1, downregulation of PD-L1 expression and degradation of mature PD-L1. Thereinto, we describe a variety of materials have been designed to target PD-L1, including antibodies, nanoparticle, peptide, aptamer, RNA, and small molecule. Additionally, we list the drugs with PD-L1 regulation capacity used in clinical and ongoing studies to explore other alternatives for targeting PD-L1 besides anti-PD-L1 monoclonal antibodies. Moreover, we discuss associated opportunities for cancer combination therapy with other modalities such as chemotherapy, radiotherapy, photodynamic therapy (PDT) and photothermal therapy (PTT), as these conventional or emerging modalities are capable of increasing the immune response of tumor cells by altering the tumor microenvironment (TME), and would display synergistic effect. At last, we give a brief summary and outlook regarding the research status and future prospect of immunotherapy.

学科与关键词

关键词
PD-L1immune checkpoint blockadetargeted therapyimmunotherapycombination therapy
相关
加载中…
  • Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy via a thermosensitive liposome system to stimulate tumor-specific immunological response (Aug, 10.1039/d1nr03288g, 2021)
    Yu, Jie; He, Xidong; Wang, Zigui; Wang, Yupeng; Liu, Sha; Xie, Zhigang; Li, Xiaoyuan*; Huang, Yubin*Nanoscale, 2021, 13(32): 13907-13907.
  • Designing Peptide-Based Nanoinhibitors of Programmed Cell Death Ligand 1 (PD-L1) for Enhanced Chemo-immunotherapy
    Xie, Fengjuan; Tang, Shasha; Zhang, Ye; Zhao, Yinbing; Lin, Yingying; Yao, Yining; Wang, Meiyan*; Gu, Zhengying*; Wan, Jingjing*ACS Nano, 2024, 18(2): 1690-1701.
  • The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
    Tang, Qing; Chen, Yun; Li, Xiaojuan; Long, Shunqin; Shi, Yao; Yu, Yaya; Wu, Wanyin*; Han, Ling*; Wang, Sumei*Frontiers in Immunology, 2022, 13: 964442.被引 57
查看全部 →

发表信息

论文状态
公开发表
发表日期
2023
卷期
第 13 卷, 第 5 期
页码
1520-1544
DOI
10.7150/thno.80091
语言
ENGLISH
成果收录
SCIE
资助标注
Hubei Province Key Laboratory of Occupational Hazard Identification and Control and Wuhan University of Science and Technology [OHIC2019 G09]; Scientific Research Project of Education Department of Hubei Province [D20211105]

作者

  • Y

    Yin, Shuangneng (第一作者)

    wuhan univ sci & technol

  • C

    Chen, Zhaojun

查看全部 4 位作者收起作者
  • C

    Chen, Dugang (通讯)

    wuhan inst technol

  • Y

    Yan, Dan (通讯)

    wuhan univ sci & technol

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417